로고

  • HOME
  • SITEMAP
  • kOREAN
Home > SmartFilm®Technology > SmartFilm®Technology

ODF overcomes the weakness of ODT
: ODT is a typical formulation developed to enhance the drug adherence for patient. The number of ODT has been
increased since 1996. ODT dissolves in mouth immediately without water, and then spread through the saliva to
throat and gastrointestinal tract. Although the ODT market is expanding rapidly, there are some limitations in the
manufacturing steps.


Better taste and convenience
: ODF can be administered whenever, wherever without water. The key point of ODF is “a good taste” and patients
prefer a sweet taste or tasteless drugs. Also, 70% of consumers prefer troches or fast dissolving tablets rather than
tablets or syrups.


Importance of DDS
: The purpose of current formulations is to give patients high compliance of drugs, feeling of comfort, and high quality
of drugs. For this purpose, creative and innovative technologies are essential. The SPC can increase the effect of
drugs using DDS which simplifies compliance of the drug and offers easy ways of administration for patients.


Ideal formulation for advanced market
: ODF can be more applicable to changes of life style more than conventional formulations. It also improves drug
adherence, safety and effectiveness, portability, convenience, and privacy protection, etc. Therefore, ODF is an
ideal formulation to advance into drug market while expanding the existing drugs.


Overcoming limits of existing ODF
: Despite many kinds of merits of ODF formulation, there are technological limits to loading dose and taste masking.
Lots of troubles exist in manufacturing process from R&D to production techniques. SPC established concrete
technical processes by commercializing products including Sildenafil citrate, Donepezil hydrochloride, Aripiprazole
and Tadalafil.


First launching
: Vultis®(Sildenafil citrate), which is the first commercializing product of SmartFilm® Technology, completed first
clinical trial and got the approval from Ministry of Food and Drug Safety (MFDS) and started marketing firstly on
May 2012 in Korea.


Building various pipelines
: It is also available to apply SmartFilm® Technology to psychoactive drugs, antiemetics, and other therapeutic
sectors in addition to Sildenafil citrate.


cGMP grade manufacturing facilities
: SmartFilm products target the regulated markets such as US and EU, as well as emerging market with cGMP
grade manufacturing facilities in Osong Bio-health Science Technopolis.


CMO business
: SPC will perform life-cycle management or Contract Manufacturing (CMO) business, as professional ODF manufactu
-rer.


Developing highly valued products
: Through deepening the long-term technologies and research, SPC will develop various high valued products
including fast-onset product, biological vaccine, and sex hormone agents etc.


In the manufacturing process of drugs, efficacy, safety, and stability are essential to ensure reproducibility of drugs.
To ensure this purpose, regulatory agencies of each developed country such as US FDA and EMA strongly demand
the cGMP and EU-GMP guideline.
Other countries also require a similar GMP guideline. Therefore, development of the technology suited for cGMP/
EU-GMP is a key component for entering the foreign markets.

SPC designed and constructed Osong factory to follow the cGMP/EU-GMP and order customized manufacturing system
from the foreign company.
In addition, from purchasing the raw material to manufacturing and shipment, the Company is planning to strictly
supervise the overall processes according to the cGMP/EU-GMP.
Through this plan, the Company is considering about entering overseas markets starting from the US and EU market
which accounts for 65% of worldwide market.